4 citations
,
February 2018 in “World journal of surgical oncology”
A young woman with kidney cancer experienced rare hair loss from a cancer drug and unusual cancer spread, suggesting early drug treatment might reduce spread and prolong survival.
The conversation discusses concerns about the potential risk of cancer from creating new hair follicles through microneedling, due to stem cell division. Specific treatments mentioned include microneedling, caffeine-containing anti-hair loss shampoos, and other unspecified topicals.
RU58841 may pose cancer risks due to its antiandrogen properties and lack of long-term safety data. Using it is considered a high-risk experiment with unknown potential for harm.
Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.
PP405 shows promise for hair follicle reactivation with minimal side effects. Users recommend continuing Minoxidil and Finasteride until more results are confirmed.
New potential hair loss treatment uses molecules from hairy moles to stimulate follicle growth. Topical solution requires less frequent application, like Botox injections a few times per year.